141 related articles for article (PubMed ID: 34538993)
1. Anti-COVID-19 activity of some benzofused 1,2,3-triazolesulfonamide hybrids using
Alzahrani AY; Shaaban MM; Elwakil BH; Hamed MT; Rezki N; Aouad MR; Zakaria MA; Hagar M
Chemometr Intell Lab Syst; 2021 Oct; 217():104421. PubMed ID: 34538993
[TBL] [Abstract][Full Text] [Related]
2. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.
Bhattacharya K; Bordoloi R; Chanu NR; Kalita R; Sahariah BJ; Bhattacharjee A
J Genet Eng Biotechnol; 2022 Mar; 20(1):43. PubMed ID: 35262828
[TBL] [Abstract][Full Text] [Related]
3.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
4. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
Udofia IA; Gbayo KO; Oloba-Whenu OA; Ogunbayo TB; Isanbor C
Netw Model Anal Health Inform Bioinform; 2021; 10(1):22. PubMed ID: 33786291
[TBL] [Abstract][Full Text] [Related]
5. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
Maurya SK; Maurya AK; Mishra N; Siddique HR
J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594
[TBL] [Abstract][Full Text] [Related]
6. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
7. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
8. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
9. Computational exploration of the dual role of the phytochemical fortunellin: Antiviral activities against SARS-CoV-2 and immunomodulatory abilities against the host.
Agrawal S; Pathak E; Mishra R; Mishra V; Parveen A; Mishra SK; Byadgi PS; Dubey SK; Chaudhary AK; Singh V; Chaurasia RN; Atri N
Comput Biol Med; 2022 Oct; 149():106049. PubMed ID: 36103744
[TBL] [Abstract][Full Text] [Related]
10. In silico docking analysis revealed the potential of phytochemicals present in
Hiremath S; Kumar HDV; Nandan M; Mantesh M; Shankarappa KS; Venkataravanappa V; Basha CRJ; Reddy CNL
3 Biotech; 2021 Feb; 11(2):44. PubMed ID: 33457171
[TBL] [Abstract][Full Text] [Related]
11. Metabologenomics approach to the discovery of novel compounds from
Melinda YN; Widada J; Wahyuningsih TD; Febriansah R; Damayanti E; Mustofa M
Heliyon; 2021 Nov; 7(11):e08308. PubMed ID: 34746476
[TBL] [Abstract][Full Text] [Related]
12. Virtual Screening of
Miandad K; Ullah A; Bashir K; Khan S; Abideen SA; Shaker B; Alharbi M; Alshammari A; Ali M; Haleem A; Ahmad S
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432204
[TBL] [Abstract][Full Text] [Related]
13. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.
Chowdhury T; Roymahapatra G; Mandal SM
Infect Disord Drug Targets; 2021; 21(4):608-618. PubMed ID: 32718300
[TBL] [Abstract][Full Text] [Related]
14. Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An
Akinlalu AO; Chamundi A; Yakumbur DT; Afolayan FID; Duru IA; Arowosegbe MA; Enejoh OA
Sci Afr; 2021 Sep; 13():e00845. PubMed ID: 34308004
[TBL] [Abstract][Full Text] [Related]
15. Silybin B and Cianidanol Inhibit M
Srivastava R; Tripathi S; Unni S; Hussain A; Haque S; Dasgupta N; Singh V; Mishra BN
Curr Pharm Des; 2021; 27(32):3476-3489. PubMed ID: 33302853
[TBL] [Abstract][Full Text] [Related]
16. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking unveils the potential of andrographolide derivatives against COVID-19: an in silico approach.
Veerasamy R; Karunakaran R
J Genet Eng Biotechnol; 2022 Apr; 20(1):58. PubMed ID: 35420322
[TBL] [Abstract][Full Text] [Related]
18. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
19. The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study.
Mishra GP; Bhadane RN; Panigrahi D; Amawi HA; Asbhy CR; Tiwari AK
Comput Biol Med; 2021 Jul; 134():104464. PubMed ID: 34020130
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach.
Zapata-Cardona MI; Florez-Alvarez L; Guerra-Sandoval AL; Chvatal-Medina M; Guerra-Almonacid CM; Hincapie-Garcia J; Hernandez JC; Rugeles MT; Zapata-Builes W
AIMS Microbiol; 2023; 9(1):20-40. PubMed ID: 36891537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
